专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2013226323A1 Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status 未知
公开(公告)号：AU2013226323A1
公开(公告)日：2014-09-11
申请号：AU2013226323
申请日：2013-02-22
申请人： NOVARTIS AG , IRM LLC
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68
摘要： Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

2. 发明专利

TN2014000337A1 未知
公开(公告)号：TN2014000337A1
公开(公告)日：2015-12-21
申请号：TN2014000337
申请日：2014-08-05
申请人： NOVARTIS AG , IRM LLC
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68

3. 发明专利

SG11201404492VA CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS 未知
公开(公告)号：SG11201404492VA
公开(公告)日：2014-10-30
申请号：SG11201404492V
申请日：2013-02-22
申请人： NOVARTIS AG , IRM LLC
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68

4. 发明专利

AU2013226323B2 Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status 未知
公开(公告)号：AU2013226323B2
公开(公告)日：2016-07-14
申请号：AU2013226323
申请日：2013-02-22
申请人： IRM LLC , NOVARTIS AG
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68
摘要： Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

5. 发明专利

ZA201405553B CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS 未知
公开(公告)号：ZA201405553B
公开(公告)日：2015-12-23
申请号：ZA201405553
申请日：2014-07-28
申请人： IRM LLC , NOVARTIS AG
发明人： NG NICHOLAS , LIU JUN , JIANG XIAOMO , HSIEH HSIN-I , HAO HUAIXIANG , CONG FENG

6. 发明专利

CA2864306A1 CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS 未知
公开(公告)号：CA2864306A1
公开(公告)日：2013-09-06
申请号：CA2864306
申请日：2013-02-22
申请人： NOVARTIS AG , IRM LLC
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68
摘要： Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

7. 发明专利

NZ627864A Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status 未知
公开(公告)号：NZ627864A
公开(公告)日：2015-12-24
申请号：NZ62786413
申请日：2013-02-22
申请人： NOVARTIS AG , IRM LLC
发明人： CONG FENG , HAO HUAIXIANG , HSIEH HSIN-I , JIANG XIAOMO , LIU JUN , NG NICHOLAS
IPC分类号： C12Q1/68
摘要： Disclosed is a method of predicting the sensitivity of tumour cell growth to inhibition by a Wnt inhibitor, comprising: a) detecting in a sample of tumour cells from a patient a level of a biomarker, where the biomarker is selected from the group consisting of: (i) DNA copy number at the RNF43 chromosomal region and/or at the ZNRF3 chromosomal region to determine a loss of heterozygosity; (ii) sequenced genomic DNA, cDNA or RNA from cancer tissues to detect an inactivation mutation in the RNF43 gene and/or the ZNRF3 gene; (iii) RNF43 mRNA expression and/or ZNRF3 mRNA expression; (iv) RNF43 protein expression and/or ZNRF3 protein expression; or (v) a combination of biomarkers (i)-(iv): b) comparing the level of the biomarker in the tumour cell sample to a control level of the biomarker selected from the group consisting of: (i) a control level of the biomarker that has been correlated with sensitivity to the Wnt inhibitor; and (ii) a control level of the biomarker that has been correlated with resistance to the Wnt inhibitor; and c) selecting the patient as being predicted to benefit from therapeutic administration of the Wnt inhibitor, if the patient’s tumour has an inactivating RNF43 or ZNRF3 mutation, if the patient’s tumour has a decreased copy number of RNF43 or ZNRF3, or the patient tumour has a decreased expression of RNF43 mRNA or protein or a decreased expression of ZNRF3 mRNA or protein indicates that the patients tumour is likely to be sensitive to Wnt inhibitor.

8. 发明专利

JP2013099334A Composition and methods of production and use for antibody of dickkopf-1 and/or -4 审中-公开
标题翻译：生产和使用DICKKOPF-1和/或-4的抗体的组合物和方法
公开(公告)号：JP2013099334A
公开(公告)日：2013-05-23
申请号：JP2012274999
申请日：2012-12-17
申请人： Novartis Ag , ノバルティスアーゲー
发明人： SHULOK JANINE , CONG FENG , FISHMAN MARK , ETTENBERG SETH , BARDROFF MICHAEL , DONZEAU MARIEL , URLINGER STEFANIE
IPC分类号： C12N15/09 , A01K67/027 , A61K39/395 , A61K45/00 , A61P1/04 , A61P3/04 , A61P3/10 , A61P17/14 , A61P19/08 , A61P19/10 , A61P21/00 , A61P25/28 , A61P29/00 , A61P35/00 , C07K16/18
CPC分类号： C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要： PROBLEM TO BE SOLVED: To provide compositions and methods for treating cancers and bone density abnormalities, including such agents that interfere or neutralize DKK1- and/or DKK4-mediated antagonism of Wnt signaling.SOLUTION: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
摘要翻译：要解决的问题：提供治疗癌症和骨密度异常的组合物和方法，包括干扰或中和DKK1和/或DKK4介导的Wnt信号传导拮抗作用的试剂。解决方案：提供与蛋白质靶标Dickkopf（DKK1）结合的抗体和片段，以及用于治疗靶细胞，特别是与溶骨性病症相关的细胞的使用方法和试剂盒。版权所有（C）2013，JPO＆INPIT

9. 发明申请

WO2013054307A3 ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES 审中-公开
标题翻译：用于WNT途径相关疾病的抗体和方法
公开(公告)号：WO2013054307A3
公开(公告)日：2013-11-21
申请号：PCT/IB2012055560
申请日：2012-10-12
申请人： NOVARTIS AG
发明人： CONG FENG , HAO HUAIXIANG , KLICKSTEIN LLOYD B , KWONG ROU-FUN , TAYLOR ANN , XIE YANG
IPC分类号： A61K38/17 , A61K39/395
CPC分类号： C07K16/40 , A61K31/40 , A61K38/53 , A61K39/3955 , A61K45/06 , C12N9/93 , C12Y603/02019 , A61K2300/00
摘要： The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of beta-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
摘要翻译：跨膜E3泛素连接酶ZNRF3和RNF43是β-连环蛋白的负调节物和真核细胞中的Wnt信号传导途径。 ZNRF3的活性可以通过抗体与其胞外结构域的结合来调节，从而导致Wnt信号传导的增加。 ZNRF3拮抗抗体可用于治疗低Wnt信号传导的疾病，如短肠综合征，骨质疏松症，糖尿病，神经退行性疾病和粘膜炎。另外，本发明的拮抗性抗体可用于增强Wnt信号传导以用于组织修复和伤口愈合。

10. 发明申请

WO2013054307A2 ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES 审中-公开
公开(公告)号：WO2013054307A2
公开(公告)日：2013-04-18
申请号：PCT/IB2012055560
申请日：2012-10-12
申请人： NOVARTIS AG
发明人： CONG FENG , HAO HUAIXIANG , KLICKSTEIN LLOYD B , KWONG ROU-FUN , TAYLOR ANN , XIE YANG
IPC分类号： A61K39/00
CPC分类号： C07K16/40 , A61K31/40 , A61K38/53 , A61K39/3955 , A61K45/06 , C12N9/93 , C12Y603/02019 , A61K2300/00
摘要： The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of beta-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式